Literature DB >> 2608697

Measurement of PGE2 as the methyl oxime by radioimmunoassay using a novel iodinated label.

R W Kelly1, B J Graham, M J O'Sullivan.   

Abstract

A radioimmunoassay has been developed for prostaglandin E2 (PGE2) using methyl oxime (MOX) derivatisation and a novel 125Iodine radiolabel. PGE2-methyl oxime (PGE2-MOX) is coupled through an imide linkage to proline in a pro-gly-tyr or similar peptide rather than through the conventional amide linkage to histamine or tyrosine methyl ester. The main advantage of this method is that the imide linkage in the label does not resemble the amide link used in the original antigen and the conjugate is therefore readily displaced by the natural PGE2. This overcomes the traditional difficulty encountered in hapten RIAs where the antiserum has a higher affinity for the label than it has for the compound to be measured. The assay that has been developed using these modifications and a solid-phase second antibody separation step, is both sensitive (with a lower detection limit of 0.5 pg/tube), reliable and simple and has the advantage that methyl oximation of the sample protects the PGE from degrading prior to and during the assay.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2608697     DOI: 10.1016/0952-3278(89)90084-7

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  9 in total

1.  Regulation of nitric oxide-like activity by prostanoids in smooth muscle of the canine saphenous vein.

Authors:  S Illiano; R Marsault; J J Descombes; T Verbeuren; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

2.  Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones.

Authors:  Michele Pier Luca Guarino; Ping Cong; Michele Cicala; Rossana Alloni; Simone Carotti; Jose Behar
Journal:  Gut       Date:  2006-12-21       Impact factor: 23.059

3.  Role of prostaglandins and histamine in hyperemic response to superficial and deep gastric mucosal injury and H+ back-diffusion in cats.

Authors:  H Gislason; H Sørbye; F Abdi-Dezfuli; H L Waldum; K Svanes
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

4.  Human cytomegalovirus-induced immunosuppression. Relationship to tumor necrosis factor-dependent release of arachidonic acid and prostaglandin E2 in human monocytes.

Authors:  M A Nokta; M I Hassan; K Loesch; R B Pollard
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

5.  Prostaglandin E2 level in tissue surrounding aseptic failed total hips. Effects of materials.

Authors:  L Sedel; J Simeon; A Meunier; J M Villette; S M Launay
Journal:  Arch Orthop Trauma Surg       Date:  1992       Impact factor: 3.067

6.  Differential release of prostaglandins by organ cultures of human fetal trachea and lung.

Authors:  R Hume; J Bell; D Cossar; M Giles; A Hallas; R Kelly
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-01       Impact factor: 2.416

7.  Human macrophages acquire a hyporesponsive state of tumor necrosis factor alpha production in response to successive Mycobacterium avium serovar 4 stimulation.

Authors:  H Gan; G W Newman; H G Remold
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

8.  Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.

Authors:  K J Sales; A A Katz; M Davis; S Hinz; R P Soeters; M D Hofmeyr; R P Millar; H N Jabbour
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

9.  Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1.

Authors:  Kurt J Sales; Arieh A Katz; Bruce Howard; Robbert P Soeters; Robert P Millar; Henry N Jabbour; Roggert P Soeters
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.